- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04271215
Overweight and Obesity as Prognostic Factors for Survival in Children With Acute Lymphoblastic Leukemia
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Data collection Information regarding sex, age at diagnosis, place of residence, white blood cell (WBC) count, immunophenotype (B or T lineage), weight and height (length when appropriate) at diagnosis, and chemotherapy protocol is collected from the patients' clinical charts by previously standardized staff. Overcrowding was used as a proxy for socioeconomic status (SES) according to the Bronfman's criteria (high SES, up to 1.5 people per room; medium-low SES, more than 1.6 people per room). The risk classification is according to the criteria of the National Cancer Institute (NCI): standard risk [ages from 1 to 9.99 years; WBC count < 50 × 109/L] or as high risk [age < 1 or ≥ 10 years or WBC ≥ 50 × 109/L].
Assessment of nutritional status at diagnosis of ALL BMI at diagnosis will be used.. Using WHO software (version 3.2.2, World Health Organization, Geneva), the BMI-for-age Z-scores were calculated for each patient. According to WHO classification, patients were categorized as normal (- 1.9999 to 0.9999), wasted (- 2 to - 2.9999), severely wasted (≥ - 3), at risk of overweight (1-1.9999), overweight (2 to 2.9999) and obesity (≥3). In addition, the BMI percentiles cutoffs provided by CDC were: normal (p5-84.9999), underweight (< p5), overweight (p85-94.9999), and obese (≥ p95). The nutritional classification and measurements validation regarding weight and height recorded in clinical files used to classify patients' nutritional status in present research has been previously described. Underweight patients were excluded from the analyses.
Sample size The sample size calculation was performed using Epi-Info version 7 software taking into account a mortality outcome frequency of 10.8% in the unexposed group (normal weight patients) and a death outcome frequency of 24% for the exposed (obese/overweight patients), a statistical power of 80% and a confidence of 95%; resulting in a total "n" of 350 overweight/obese patients to be compared with the rest of the cohort that are not overweight and obese.
Statistical analysis Descriptive statistics and relative risks (RR) calculation with 95% confidence intervals (CI) will be carried out. Kaplan-Meier survival analysis will be conducted. Log-rank test will be calculated. The analyses will be conducted independently for disease-free-survival (DFS) or overall survival (OS), adjusting for variables whose effects on the studied outcomes have been previously documented (age, sex, socioeconomic status, immunophenotype, NCI risk classification, and chemotherapy protocol). A Cox proportional hazard model will be used. Hazard ratios (HR) with 95% CIs will be calculated.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
-
Mexico City, Mexiko, 02990
- Centro Médico Nacional Hospital General La Raza, IMSS
-
Mexico City, Mexiko, 03103
- Hospital General Regional Num 1 Carlos McGregor Sánchez Navarro, IMSS
-
Mexico City, Mexiko, 06720
- Hospital de Pediatria "Dr. Silvestre Frenk Freund" CMN Siglo XXI, IMSS
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Patients under 15 years of age
- Newly diagnosed with acute lymphoblastic leukemia
- Diagnosis confirmation by bone marrow aspiration and immunophenotype
- Attended in the participating Hospitals.
Exclusion Criteria:
- Patients with Down Syndrome (for being a population with different disease behavior and cytogenetic alterations than patients without this genetic condition)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Overweight/Obesity
BMI at diagnosis will be used.
Using WHO software (version 3.2.2,
World Health Organization, Geneva), the BMI-for-age Z-scores were calculated for each patient.
According to WHO classification, patients were categorized as normal (- 1.9999 to 0.9999), wasted (- 2 to - 2.9999), severely wasted (≥ - 3), at risk of overweight (1-1.9999),
overweight (2 to 2.9999) and obesity (≥3).
In addition, the BMI percentiles cutoffs provided by CDC were: normal (p5-84.9999),
underweight (< p5), overweight (p85-94.9999),
and obese (≥ p95).
The nutritional classification and measurements regarding weight and height recorded in clinical files will be used to classify patients' nutritional status in present research has been previously described.
|
Chemotherapy protocol used in each participating hospital
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Overall survival
Zeitfenster: year 5
|
Deaths of patients occurring during the follow-up period will be collected.
The cause of death and the date that this occurred will be also registered.
In the case of patients alive at the end of follow-up, the date of the last visit to the hospital will be collected.
|
year 5
|
Disease-free survival
Zeitfenster: year 5
|
Clinical data and by complementary examinations indicating that there is reappearance of the disease after complete remission has been achieved, presence of blasts > 5% in bone marrow (bone marrow relapse) or presence of blasts in cerebrospinal fluid fluid (CNS relapse), testicular infiltration by blasts in the biopsy (testicular relapse), combined (bone marrow/CNS) at any time during treatment .
In case the patient has relapsed, the site of relapse will be collected (bone marrow, CNS, testicle, ovary, eye, etc.).
|
year 5
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Juan M Mejía-Arangure, PhD, Instituto Mexicano del Seguro Social/Instituto Nacional de Medicina Genomica
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Lymphoproliferative Erkrankungen
- Lymphatische Erkrankungen
- Immunproliferative Erkrankungen
- Überernährung
- Ernährungsstörungen
- Körpergewicht
- Fettleibigkeit
- Leukämie
- Übergewicht
- Vorläuferzelle lymphoblastische Leukämie-Lymphom
- Leukämie, lymphatisch
Andere Studien-ID-Nummern
- R-2015-785-070
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Leukämie, Lymphoblast
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... und andere MitarbeiterUnbekanntAllogene hämatopoetische Stammzelltransplantation | Bedingungen | Mixed-Lineage-Leukemia (MLL)-Rearranged Acute LeukemiaChina
-
Shenzhen Second People's HospitalRekrutierungLeukämie | Myeloisch | Chronisch | BCR-ABL (Breakpoint Cluster Region-Abelson Murine Leukemia) | PositivChina
Klinische Studien zur Chemotherapy protocol used
-
Universidad de MurciaAbgeschlossen
-
Guangzhou University of Traditional Chinese MedicineUnbekanntUntersuchung des Zusammenhangs zwischen der Einhaltung von HHEP nach ISTIA und Schlaganfallrezidiven oder kardiovaskulären Ereignissen.China
-
University of British ColumbiaB.C. Rehabilitation FoundationAbgeschlossenDünnflüssige DysphagieKanada
-
Universitaire Ziekenhuizen KU LeuvenAbgeschlossen
-
Imam Abdulrahman Bin Faisal UniversityAbgeschlossenOsteoporoseSaudi-Arabien
-
Universitat Internacional de CatalunyaInstitut Investigacio Sanitaria Pere VirgiliAbgeschlossenSchlaganfall-FolgenSpanien
-
William Beaumont HospitalsFoundation for Education and Research in Neurological EmergenciesAbgeschlossenTransitorische ischämische AttackeVereinigte Staaten
-
Methodist Health SystemRekrutierung
-
Grupo Español de Rehabilitación MultimodalInstituto de Salud Carlos III; Instituto de Investigación Sanitaria AragónRekrutierung
-
Hospital for Special Surgery, New YorkRekrutierungHüftoperation | Opioidgebrauch | AkupunkturVereinigte Staaten